Technical Analysis for ONCT - Oncternal Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical ONCT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 0.19% | |
| Bollinger Band Squeeze | Range Contraction | 0.19% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.19% | |
| Lower Bollinger Band Touch | Weakness | 0.19% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | about 16 hours ago |
| Possible NR7 | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Down 1% | about 19 hours ago |
| Up 1% | about 20 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/04/2021
Oncternal Therapeutics, Inc. Description
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Solid Tumors Treatment Of Cancer Cancers Chemical Compounds Monoclonal Antibody Organic Compounds Drug Development Sarcoma Treatment Of Cancers Hematologic Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.55 |
| 52 Week Low | 1.49 |
| Average Volume | 1,090,263 |
| 200-Day Moving Average | 4.95 |
| 50-Day Moving Average | 5.67 |
| 20-Day Moving Average | 5.44 |
| 10-Day Moving Average | 5.34 |
| Average True Range | 0.35 |
| ADX | 10.69 |
| +DI | 15.05 |
| -DI | 18.88 |
| Chandelier Exit (Long, 3 ATRs) | 4.82 |
| Chandelier Exit (Short, 3 ATRs) | 6.04 |
| Upper Bollinger Bands | 5.75 |
| Lower Bollinger Band | 5.12 |
| Percent B (%b) | 0.12 |
| BandWidth | 11.62 |
| MACD Line | -0.13 |
| MACD Signal Line | -0.14 |
| MACD Histogram | 0.0086 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.46 | ||||
| Resistance 3 (R3) | 5.46 | 5.37 | 5.41 | ||
| Resistance 2 (R2) | 5.37 | 5.31 | 5.37 | 5.40 | |
| Resistance 1 (R1) | 5.29 | 5.27 | 5.25 | 5.29 | 5.38 |
| Pivot Point | 5.20 | 5.20 | 5.18 | 5.20 | 5.20 |
| Support 1 (S1) | 5.12 | 5.14 | 5.08 | 5.12 | 5.02 |
| Support 2 (S2) | 5.03 | 5.10 | 5.03 | 5.00 | |
| Support 3 (S3) | 4.95 | 5.03 | 4.99 | ||
| Support 4 (S4) | 4.95 |
